A performance coach shares his own checklist for people beginning retatrutide, the Lilly drug that is still in trials and not approved.
Recap by typeshit. Full story at Nicholas Trigili | Human Performance Specialist.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Researchers reviewed 100 popular videos with nearly 46 million views. None were labeled as ads, though promoting prescription drugs is illegal in the UK.
Adding an experimental hormone mimic to tirzepatide pushed body mass reduction as high as 23.3% in a Lilly clinical trial, per NewsBytes.
Loading…